



lavie bio
better by nature

Introduction to Lavie Bio

August 2020

Forward looking statement



This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries, including Lavie Bio Ltd. ("Lavie Bio") (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Lavie Bio claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Lavie Bio and Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Lavie Bio's and Evogene's control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Lavie Bio and Evogene disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Our Mission

Improve food quality,
sustainability and agricultural
productivity through microbiome
based ag-biological products

\$250B – Annual agriculture Input Market



Fertilizers (~59%) – material of natural / synthetic origin applied to soil in order to supply plant nutrients essential for plant growth

Ag-Chemicals (~24%) – Pesticides (herbicides, insecticides & fungicides) and crop enhancers

Seeds & Seed Traits (~15%) – Seeds & improved seed traits via GMO / Breeding / Genome editing

Ag-Biologicals (~3%) – externally-applied products derived from natural, biological sources such as microbials, macrobials, biochemicals and minerals to minimize plant stress or maximize plant health

Note: Pie chart depicts estimated split of agricultural input market in 2019.
Source: MarketsandMarkets, industry publications.

Agriculture market is going through a shift

Consumer preferences are driving the change and impact regulators

Consumers focus



Consumer focus: Quality & sustainability

- Healthier produce
- Environmentally sustainable
- While maintaining crop productivity



Farmer focus




Farm focus: Productivity & profitability

- Application cost
- Compatibility
- Resistance management

The Ag-Biologicals opportunity

Ag-Biologicals market expected to double in size in the next 5 years; forecasted to gain meaningful share from traditional crop protection and fertilizers chemicals



- Ag-Biologicals represent the fastest growing agriculture inputs segment with **CAGR of 13.7%***
- Targeting the segments of traditional **chemicals crop protection** and **fertilizers**
- **Current growth** ('Wave 1') mainly from existing products
- **Future growth** ('Wave 2') is about new value derived from new technologies

Breaking the biologicals “glass ceiling”

Future growth is dependent on the ability to address key product challenges of:
1) Efficacy 2) consistency 3) Commercial Viability

*Source: MarketsandMarkets, industry publications

Microbiome: The Ag-Biologicals promise

Billions of microbes matters!


Tapping into untapped source of diversity - addressing the challenges of efficacy, consistency and commercial viability

**Integral in
Plant's eco-system**




M's of interactions

**Nature's largest
'function bank'**



M's of functions

**'Live Engine'
producing in the field**



Along plant's lifecycle

Harnessing the Power of microbiome

Technology: Biology Driven Design (BDD) platform



Decoding the complex interaction: microbiome - plant – environment

Harnessing the microbiome functionality

- **Amplify the positive**
- **Eliminate the negative**
- **Retrieve lost**

Powered by:




Evogene's CPB platform




Taxon technology platform*

A.I driven holistic platform, harnessing the power of computational genomics



Diversity



System Modeling



Genomic Prism




Function hub



Design

Unleashing the potential of live microbial products

Our breakthrough biology driven design approach allows us to *identify* candidate products out of millions potential candidates...



...but more importantly, to *optimize* the product attributes, bridging the gap to a viable live microbial product

Go To Market (GTM) strategy

Direct Lavie Bio Product



- Non – consolidated segments
- Commercialization through channels
- Revenue from sales

Indirect 'Lavie Inside'



- Consolidated segments
- Commercialization through partner's channels
- Revenue from R&D / Milestones and royalties

3rd party products 'The Lavie Spark'



- Precision Optimization of 3rd party's products
- Short time to market
- Revenue from sales or R&D / Milestones and royalties

Product Pipeline

Product Program	Product focus	Target market*	Potential expansion	Discovery	Pre-Development	Development Stage1	Development Stage2	Pre-Commercialization	Product
Bio-Stimulants									
LAV 211, 212	Seed treatment, Spring Wheat North America 	25M ACRES wheat North America	500M ACRES						2022
LAV 213, 218	Seed treatment Corn North America Europe 	120M ACRES, corn US, EU	180M ACRES						Conf.**
Bio-Pesticides									
LAV 311, 321 Fruit rots	Foliar F&V Europe North America 	>200M\$ grapes chemicals usage	+\$150M Additional F&V						2024
LAV 321, 322 Downey mildew	Foliar F&V Europe North America 	>350M\$ grapes chemicals usage	+\$150M Additional F&V						2025
LAV 331, 332 Seedlings disease (Pythium)	Seed Treatment, Corn, soy, F&V North America Europe 	>\$500M	<\$200M						Conf.**
LAV 441, 442 Bio-Insecticides	Seed Treatment, Corn, foliar soy North America Europe 	>\$1.5B existing traits and chemicals market	<\$500M						Conf.**

** May include proprietary partner information

Confidential

LAV 211 - Improving spring wheat yield


1ST focus market – 25M acres (ND, MT, West Canada)

Target market for first product launch: ±25M acres in North Dakota and Western Canada

20 - 50\$ Potential farmer benefit per acre

75% win-rate with 6% yield across years, locations and genetic backgrounds (p value < 0.05)

- Up to 25% yield increase in top performing locations





LAV 311 Comparable to chemical pesticides

Estimated* \$1B existing chemicals pesticides market for top 3 grapes diseases



LAV 311 Vineyard Validation Against Fruit Rot of Grape Caused by *Botrytis cinerea*

Results of LAV_311 in Vineyard trials from Target geography (Italy)



Foliar application

* p -value < 0.05

- Mock
- Chemical Product
- Ag-Biological product
- LAV311

Established 'End to End' capabilities (Israel and US)



Management Team



Ido Dor
CEO

*Leadership experience
of 20+ years in
business
development, sales
and channel
management*



Michael Ionesco
VP Research

*Innovative research
leader with deep
biotechnology, big
data and
informatics
expertise*



Amir Bercovitz
VP Development

*Extensive development
and product expertise
in the ag-biologicals
field for 30+ years – led
introductions of 5
commercials products*



James Presnail
COO

*25+ years broad
industrial experience
serving in leadership
roles of complex
agricultural product
development programs
and management*



Dorit Kriener
CFO

*20+ years of experience
in corporate finance,
public and private
fundraising, strategy
and accounting
management*



Board members



Ofer Haviv
*Chairman of the board,
Evogene CEO*



Kristian Bjorneboe
*Seasoned business
development leader*



Rowdy Smith
*Global Portfolio Leader for
the Seed Applied & Biological
Technologies for Corteva
Agriscience™*



Trevor Thissen
*Senior agriculture
executive, experienced in
marketing, sales, and
go-to-market*



Corteva Investment in Lavie Bio





Search


WHO WE ARE | OUR IMPACT | PRODUCTS & SERVICES | BLOG | MEDIA CENTER

Press Release • 8/7/2019

Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

Investment Includes Equity and Corteva's Shares in Taxon Biosciences for Shares in Lavie Bio

Wilmington, Del., USA and Rehovot, Israel – Aug. 7, 2019 – Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene's agriculture biologicals subsidiary,



Planned milestone roadmap

2020



- ✓ LAV211 product pre-commercialization phase
- ✓ Establishment of commercial team and GTM channels
- ✓ Further product advancement

2022



- ✓ First product launch (\$sales)
- ✓ Products advancement in regulation process
- ✓ Strategic and Optimization collaborations

2024



- ✓ Product portfolio expansion – product launches (\$sales)
- ✓ Precision Optimization product – Pre-Launch
- ✓ Established market channels

A close-up photograph of a hand holding a golden wheat stalk. The hand is positioned in the upper right corner, with fingers gently gripping the stalk. The wheat stalks are ripe and golden-brown, with long awns. The background is a vast field of similar wheat stalks, slightly out of focus. A dark green diagonal shape covers the left side of the image, serving as a background for the text.

THANK YOU

www.lavie-bio.com

